Floatz logo

FLUOROURACILUM

Apatinib

Huashan HospitalSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Apatinib cohort.

Asset / SponsorPhaseRating
Rivoceranib
The First Affiliated Hospital of Xiamen University
Phase 3BB
Eloxatin
Guohui Xu
Phase 3B
Carboplatin
The First Affiliated Hospital of Xiamen University
Phase 2B
Inno-206
Guohui Xu
Phase 3B
ETOPOSIDE
The First Affiliated Hospital of Xiamen University
Phase 2CCC
Adebrelimab
The First Affiliated Hospital of Xiamen University
Phase 2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
West China Hospital
Phase 1/2CC
Capecitabine
Nanchong Central Hospital
N/AD

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →